View this email in your browser


Stop Calling Biden’s Radical Health Agenda ‘Moderate’

Forbes.com | Sally C. Pipes
April 27, 2020

Biden intends to spend $750 billion over the next decade to expand the federal government’s involvement in health care. He’d begin by lowering Medicare’s eligibility age to 60. That change would qualify 20 million additional people for the program. Medicare can barely cover the cost of caring for its current beneficiaries. The program will exhaust its hospital insurance trust fund by 2026.
Read the new brief by PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy Sally Pipes arguing that proposals for new “Buy America” mandates could reduce patient access and damage the economy.


Dr. Henry Miller Quoted in Yahoo! on Coronavirus, Hydroxychloroquine Debate

Yahoo! Finance | Anjalee Khemlani
April 25, 2020

Yet according to Henry Miller, founding director of the FDA’s Office of Biotechnology and a Senior Fellow at the Pacific Research Institute, Trump’s public advocacy of the treatment — and the FDA’s initial decision to authorize an emergency use order — gave the debate a needlessly political veneer. “It’s an example of an FDA action that in a sense was unnecessary…probably politically motivated,” Miller told Yahoo Finance in a recent interview. He also blasted the FDA’s emergency use authorization as unnecessary, because the drug is already approved for off-label uses like lupus and rheumatoid arthritis.

Read more. . .


Coronavirus fight – Would ‘Medicare-for-all’ have improved US response to COVID-19?

Fox News | Sally C. Pipes
April 27, 2020

But “Medicare-for-all” would not have improved our nation’s response to the outbreak. Other countries with socialized medicine have struggled mightily to combat COVID-19. In fact, the United States would have been even less prepared for the pandemic under “Medicare-for-all.”


Dr. Henry Miller in Wall Street Journal: A Coronavirus Vaccine: Faster, Please

The Wall Street Journal | Henry Miller, M.S., M.D.
April 22, 2020

Covid-19 cases, hospitalizations and deaths are leveling off in hot spots like Seattle and New York. New infections should soon begin to decline, and many parts of the country will be able to start a phased return to “normal.” Yet without a vaccine, normality will look very different than it did before the pandemic.

The PRI Center for Medical Economics and Innovation released the third video in its series about explaining drug innovation costs. Watch Professor Salvare take Pete Paystoomuch in a time machine to learn how drugs become cheaper after higher initial costs that incentivize innovation, going up the “prescription escalator” to learn why so much is spent on prescription drugs despite the mass use of cheaper generics.
Copyright © 2020 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
101 Montgomery Street, Suite 1300, San Francisco, CA 94104



Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.